Singapore markets closed
  • Straits Times Index

    +10.72 (+0.33%)
  • S&P 500

    -31.16 (-0.72%)
  • Dow

    -171.69 (-0.50%)
  • Nasdaq

    -164.43 (-1.25%)

    -296.90 (-1.25%)
  • CMC Crypto 200

    -14.29 (-2.49%)
  • FTSE 100

    -4.14 (-0.06%)
  • Gold

    +6.10 (+0.34%)
  • Crude Oil

    +0.93 (+1.06%)
  • 10-Yr Bond

    0.0000 (0.00%)
  • Nikkei

    -280.63 (-0.96%)
  • Hang Seng

    -158.54 (-0.80%)
  • FTSE Bursa Malaysia

    -1.54 (-0.10%)
  • Jakarta Composite Index

    +53.10 (+0.74%)
  • PSE Index

    +5.64 (+0.08%)

Global Uterine Leiomyoma (Uterine Fibroids) Clinical Trials Research Report, H2 2021 Edition -

·2-min read

DUBLIN, December 01, 2021--(BUSINESS WIRE)--The "Uterine Leiomyoma (Uterine Fibroids) - Global Clinical Trials Review, H2, 2021" clinical trials has been added to's offering.

"Uterine Leiomyoma (Uterine Fibroids) - Global Clinical Trials Review, H2, 2021" provides an overview of the Uterine Leiomyoma (Uterine Fibroids) Clinical trials scenario.

This report provides top line data relating to the clinical trials on Uterine Leiomyoma (Uterine Fibroids). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe.

The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.


  • The report provides a snapshot of the global clinical trials landscape

  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

  • The Report provides enrollment trends for the past five years

  • Report provides latest news for the past three months

Key Topics Covered:

  • Report Guidance

  • The Publisher's Clinical Trials Report Coverage

  • Clinical Trials by Region

  • Clinical Trials and Average Enrollment by Country

  • Clinical Trials by G7 Countries: Proportion of Uterine Leiomyoma (Uterine Fibroids) to Non Malignant Disorders Clinical Trials

  • Clinical Trials by Phase in G7 Countries

  • Clinical Trials in G7 Countries by Trial Status

  • Clinical Trials by E7 Countries: Proportion of Uterine Leiomyoma (Uterine Fibroids) to Non Malignant Disorders Clinical Trials

  • Clinical Trials by Phase in E7 Countries

  • Clinical Trials in E7 Countries by Trial Status

  • Clinical Trials by Phase

  • In Progress Trials by Phase

  • Clinical Trials by Trial Status

  • Clinical Trials by End Point Status

  • Subjects Recruited Over a Period of Time

  • Clinical Trials by Sponsor Type

  • Prominent Sponsors

  • Top Companies Participating in Uterine Leiomyoma (Uterine Fibroids) Therapeutics Clinical Trials

  • Prominent Drugs

  • Clinical Trial Profile Snapshots

  • Appendixids) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2021

Companies Mentioned

  • AbbVie Inc

  • Bayer AG

  • Neurocrine Biosciences Inc

  • Richter Gedeon Nyrt

  • Takeda Pharmaceutical Co Ltd

  • ObsEva SA

  • Sumitomo Dainippon Pharma Co Ltd

  • Sumitovant Biopharma Ltd

  • Astellas Pharma Inc

  • Abbott Laboratories

For more information about this clinical trials report visit

View source version on

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting